AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront
AstraZeneca is partnering with Quell Therapeutics to develop regulatory T cell therapies for type 1 diabetes and inflammatory bowel disease, joining the growing movement of companies and academic groups developing cell therapies for autoimmune diseases.
AstraZeneca will pay Quell, a London-based biotech, $85 million upfront, with a potential $2 billion on the line in downstream milestones, plus royalties. The duo will work together on developing two regulatory T cell therapies (or Treg therapies), both of which are still preclinical. Quell is in charge of manufacturing the therapies until the end of the first clinical trials, after which AstraZeneca has the option to license, develop and commercialize the treatments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.